Drotrecogin alfa activated (DAA) was approved for treatment of patients with severe sepsis in 2001 based on a large randomized double-blind clinical trial, PROWESS [1] . A second randomized clinical trial, PROWESS-SHOCK [2], was recently completed, but the survival benefi ts observed with the original trial were not reproduced in the second trial. Th e results from PROWESS-SHOCK culminated in the removal of this drug from the market in 2011. Both trials were multicenter, randomized, and double-blinded, and both used the same drug manufacturer. Which trial should we believe in? What should be done while one-third of our patients with severe sepsis are still dying despite the best standard of care? Our paper aims to explore the reasons for this discrepancy and off er new solutions.
Th e statistical heterogeneity analysis demonstrates that the vast majority (80 to 90%) of the detected heterogeneity regarding survival outcomes between these trials could not be explained by chance. Th is is quite remarkable because it points out that the reasons for this large heterogeneity derive from diff erences related to the trials themselves, in this case, patient population, baseline infection, and co-interventions. Moreover, even after we stratifi ed the survival outcome analysis by disease severity, the elevated heterogeneity did not change. We conjecture that the diff erent clinical characteristics and co-interventions were most likely the cause for this irreversible statistical heterogeneity.
Another complicating factor is that the PROWESS-SHOCK trial was substantially underpowered: 42% proba bility of false-negative results. Although a frequent question since the completion of PROWESS-SHOCK has been 'which trial should we believe in?' , we propose that this is not the 64 million-dollar question; the one that is begging for an answer is 'will we ever be able to replicate the design of the PROWESS trial?' If we aim for a control mortality of 35%, the answer is 'no' because recent phase III trials [2, 4] have shown that the mortality associated with severe sepsis now ranges from 24 to 28%. If we slightly modify the question to 'can we perform another phase III trial on DAA with adequate statistical power?' , the answer is yes on two accounts: 1) a large sample size (N = 2,500 to 3,000) would fulfi ll the frequentist (classical) statistical approach; and 2) a smaller sample size (500 to 1,000) would fulfi ll the adaptive Bayesian statistical approach, as we explained in a previous manuscript [5] . What about fi nancial support? Th e fi nancial and logistic challenges would be enormous for the frequentist approach, but defi nitely more feasible for th e Bayesian approach. Would it be ethical to perform a third trial? Yes, a study we published recently [6] demonstrated that, in real-life application outside phase III trials, DAA signifi cantly reduced in-hospital mortality by 18% (95% confi dence interval 13 to 22%) in patients with severe sepsis (N = 41,401 patients). How would this trial be designed? First, an individual-patient data meta-analysis to combine all randomized trials at the patient-level would provide the most accurate and statistically powerful way to reduce the current scientifi c uncertainty; second, the concomitant use of both frequentist and Bayesian methodologies [7] would maximize the opportunity to gather the most valuable scientifi c information on the effi cacy of DAA; and third, the fi ndings from this new analysis would provide the necessary tools to optimize the design of the next randomized trial. Th us, it is our responsibility to not stop our scientifi c investigation here, especially considering that the 3,370 patients who gave their consent to participate in these clinical trials were assured that their information would be fully utilized for fostering progress in medical science and for the betterment of future patients affl icted by severe sepsis.
Conclusion
PROWESS and PROWES-SHOCK trials are not comparable based on both clinical and statistical heterogeneity. Hence, the true eff ect of DAA in patients with severe sepsis remains to be defi ned. Unless the totality of the available evidence is thoroughly evaluated through an individual-patient data meta-analysis, and an adaptive Bayesian clinical trial is performed, we will continue treating our patients with the appalling sensation that we are not improving their survival due to our own inability to advance the quality of clinical research in the sepsis fi eld.
